RxDoctor Payments Data

Muhammad Shamim, MD

Internal Medicine · Brownsville, TXNPI 1326085796

Payments from drug & device makers

$1,827in general payments, 2019–2025

Across 58 payments — averaging $31.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$335
  • Amgen$284
  • Radius Health, Inc.$270
  • Boston Scientific$178
  • GSK$167
  • UCB, Inc.$163
  • plus $430 from 5 others

What the payments were for

  • Food & beverage$1,43278%
  • Education$39522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,827 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$4,646
Medicare patients
69
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orencia ClickjectAbatacept196$1,161,834
ForteoTeriparatide160$709,974
Humira(Cf) PenAdalimumab100$676,022
Enbrel MiniEtanercept85$623,032
Teriparatide173$381,152
Actemra ActpenTocilizumab81$380,490
BenlystaBelimumab70$377,858
Cosentyx Unoready PenSecukinumab36$262,949
Humira PenAdalimumab37$243,175
ProliaDenosumab138$231,248
Skyrizi PenRisankizumab-Rzaa11$218,180
Cosentyx Sensoready PenSecukinumab30$205,927
Enbrel SureclickEtanercept23$180,040
KevzaraSarilumab34$140,026
OrenciaAbatacept22$128,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$57$709,974160 claims
GSKBenlysta$167$377,85870 claims
AmgenProlia$284$231,248138 claims
E.r. Squibb & Sons, L.L.C.Orencia$143$128,96222 claims
Johnson & JohnsonSimponi$335$104,88418 claims
Radius Health, Inc.Tymlos$270$47,85418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →